Numerous clinical cases of patients with ALK-driven cancers who were treated with ALK inhibitors have reported visual impairment as a common side effect, with symptoms such as blurred vision, lowered visual acuity, presbyopia, flashes, and accommodation disorders being strongly correlated with ALK inhibitors [88,97]. Here, ALK is linked to presbyopia.